Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Percheron Therapeutics ( (AU:PER) ) has shared an update.
Percheron Therapeutics Limited has announced a change in the interest of its director, Charmaine Gittleson, in the company’s securities. The change involves the acquisition of 239,999 unquoted options exercisable at 3.5 cents per option, issued under the company’s Bonus Offer. This adjustment in the director’s interest reflects the company’s ongoing strategic initiatives to align its leadership’s interests with its operational goals.
The most recent analyst rating on (AU:PER) stock is a Buy with a A$0.24 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
More about Percheron Therapeutics
Average Trading Volume: 4,227,335
Technical Sentiment Signal: Sell
Current Market Cap: A$10.87M
For a thorough assessment of PER stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- Intel Stock (NASDAQ:INTC) Slips Despite Growing Interest in AI
- “…Tied to the Effort From the Administration” Boeing Stock (NYSE:BA) Blasts Up as Boeing Counts on New Top Sales Rep in China: President Trump
- “We Do Not Have Conflicting Interests….” Microsoft Stock (NASDAQ:MSFT) Gains on New Plan to be the Agentic AI Internet’s Backbone